Clinical significance of fragmented red cells after allogeneic bone marrow transplantation

To clarify the clinical significance of the presence of fragmented red cells (FRC) after allogeneic bone marrow transplantation (BMT), we measured the incidence and degree of FRC and their relationships to clinical features. The percentages of FRC (%FRC) were measured in 50 patients on weeks -2, 0,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of hematology 2003-02, Vol.77 (2), p.180-184
Hauptverfasser: KANAMORI, Heiwa, TAKAISHI, Yumiko, ISHIGATSUBO, Yoshiaki, TAKABAYASHI, Maki, TANAKA, Masatsugu, YAMAJI, Satoshi, TOMITA, Naoto, FUJIMAKI, Katsumichi, FUJISAWA, Shin, WATANABE, Shinichiro, MATSUZAKI, Michio
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 184
container_issue 2
container_start_page 180
container_title International journal of hematology
container_volume 77
creator KANAMORI, Heiwa
TAKAISHI, Yumiko
ISHIGATSUBO, Yoshiaki
TAKABAYASHI, Maki
TANAKA, Masatsugu
YAMAJI, Satoshi
TOMITA, Naoto
FUJIMAKI, Katsumichi
FUJISAWA, Shin
WATANABE, Shinichiro
MATSUZAKI, Michio
description To clarify the clinical significance of the presence of fragmented red cells (FRC) after allogeneic bone marrow transplantation (BMT), we measured the incidence and degree of FRC and their relationships to clinical features. The percentages of FRC (%FRC) were measured in 50 patients on weeks -2, 0, 2, 4, 6, 8, 10, and 12. The %FRC in pre-BMT patients (mean, 0.52%; range, 0.04%-1.56%) was higher than in healthy control subjects (mean, 0.08%; range, 0.02%-0.27%). The highest %FRC (> or = 1.3%) were seen in 2 pre-BMT and 17 post-BMT patients. Eight patients who developed thrombotic microangiopathy (TMA) showed %FRC values that were significantly higher than those in patients without TMA. However, the timing of elevated %FRC was delayed until several days after the onset of intravascular hemolysis and/or a drop in platelet count. Of the patients who did not experience TMA, 5 patients with infection and 4 patients with acute graft-versus-host disease (GVHD) also showed significant elevation of %FRC during the clinical course. Furthermore, multivariate analysis results demonstrated that TMA and infection had a statistically significant effect on the high value of %FRC. These findings indicate that the appearance of FRC is a common phenomenon in patients undergoing BMT and is not a predictive factor for the early diagnosis of TMA, although FRC is one of the main laboratory findings in TMA. Furthermore, an increased %FRC is seen in other post-BMT clinical settings, such as infection and acute GVHD.
doi_str_mv 10.1007/BF02983218
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73090048</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1879945031</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-697c031cd6cfc4009a4e9f8e16106ea92b5bd11e6103af1c506ab8d6440000d93</originalsourceid><addsrcrecordid>eNpd0E1rGzEQBmBRGhLn49IfUEQhORQ2HUkraXVsTZIGAr2kl1wWrXZkZNaSK60p-fdRsMGQw6ARPAwzLyFfGNwyAP3j1z1w0wnOuk9kwTolG6F1-5kswHDZSM3gjJyXsgZgGlp9Ss4YV1x3Ui7Iy3IKMTg70RJWMfjaRoc0eeqzXW0wzjjSXMvhNBVq_YyZ2mlKK4wYHB1SRLqxOaf_dM42lu1k42znkOIlOfF2Knh1eC_I3_u75-Xv5unPw-Py51PjhBFzo4x2IJgblfOuBTC2ReM7ZIqBQmv4IIeRMaxfYT1zEpQdulG11QKMRlyQm_3cbU7_dljmfhPK-7o2YtqVXgswAG1X4bcPcJ12Odbdes606DgXuqLve-RyKiWj77c51ANfewb9e9z9Me6Kvx4m7oYNjkd6yLeC6wOwpYZcM40ulKNrJQempHgDtQ6Ggg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217382237</pqid></control><display><type>article</type><title>Clinical significance of fragmented red cells after allogeneic bone marrow transplantation</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>KANAMORI, Heiwa ; TAKAISHI, Yumiko ; ISHIGATSUBO, Yoshiaki ; TAKABAYASHI, Maki ; TANAKA, Masatsugu ; YAMAJI, Satoshi ; TOMITA, Naoto ; FUJIMAKI, Katsumichi ; FUJISAWA, Shin ; WATANABE, Shinichiro ; MATSUZAKI, Michio</creator><creatorcontrib>KANAMORI, Heiwa ; TAKAISHI, Yumiko ; ISHIGATSUBO, Yoshiaki ; TAKABAYASHI, Maki ; TANAKA, Masatsugu ; YAMAJI, Satoshi ; TOMITA, Naoto ; FUJIMAKI, Katsumichi ; FUJISAWA, Shin ; WATANABE, Shinichiro ; MATSUZAKI, Michio</creatorcontrib><description>To clarify the clinical significance of the presence of fragmented red cells (FRC) after allogeneic bone marrow transplantation (BMT), we measured the incidence and degree of FRC and their relationships to clinical features. The percentages of FRC (%FRC) were measured in 50 patients on weeks -2, 0, 2, 4, 6, 8, 10, and 12. The %FRC in pre-BMT patients (mean, 0.52%; range, 0.04%-1.56%) was higher than in healthy control subjects (mean, 0.08%; range, 0.02%-0.27%). The highest %FRC (&gt; or = 1.3%) were seen in 2 pre-BMT and 17 post-BMT patients. Eight patients who developed thrombotic microangiopathy (TMA) showed %FRC values that were significantly higher than those in patients without TMA. However, the timing of elevated %FRC was delayed until several days after the onset of intravascular hemolysis and/or a drop in platelet count. Of the patients who did not experience TMA, 5 patients with infection and 4 patients with acute graft-versus-host disease (GVHD) also showed significant elevation of %FRC during the clinical course. Furthermore, multivariate analysis results demonstrated that TMA and infection had a statistically significant effect on the high value of %FRC. These findings indicate that the appearance of FRC is a common phenomenon in patients undergoing BMT and is not a predictive factor for the early diagnosis of TMA, although FRC is one of the main laboratory findings in TMA. Furthermore, an increased %FRC is seen in other post-BMT clinical settings, such as infection and acute GVHD.</description><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/BF02983218</identifier><identifier>PMID: 12627855</identifier><language>eng</language><publisher>Tokyo: Springer</publisher><subject>Adolescent ; Adult ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Bone Marrow Transplantation - adverse effects ; Bone marrow, stem cells transplantation. Graft versus host reaction ; Case-Control Studies ; Erythrocytes - pathology ; Female ; Hemolysis ; Hemolytic-Uremic Syndrome - blood ; Hemolytic-Uremic Syndrome - diagnosis ; Hemolytic-Uremic Syndrome - etiology ; Humans ; Incidence ; Infection - blood ; Male ; Medical sciences ; Middle Aged ; Predictive Value of Tests ; Purpura, Thrombotic Thrombocytopenic - blood ; Purpura, Thrombotic Thrombocytopenic - diagnosis ; Purpura, Thrombotic Thrombocytopenic - etiology ; Risk Factors ; Time Factors ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; Transplantation, Homologous</subject><ispartof>International journal of hematology, 2003-02, Vol.77 (2), p.180-184</ispartof><rights>2003 INIST-CNRS</rights><rights>The Japanese Society of Hematology 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-697c031cd6cfc4009a4e9f8e16106ea92b5bd11e6103af1c506ab8d6440000d93</citedby><cites>FETCH-LOGICAL-c393t-697c031cd6cfc4009a4e9f8e16106ea92b5bd11e6103af1c506ab8d6440000d93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14520165$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12627855$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KANAMORI, Heiwa</creatorcontrib><creatorcontrib>TAKAISHI, Yumiko</creatorcontrib><creatorcontrib>ISHIGATSUBO, Yoshiaki</creatorcontrib><creatorcontrib>TAKABAYASHI, Maki</creatorcontrib><creatorcontrib>TANAKA, Masatsugu</creatorcontrib><creatorcontrib>YAMAJI, Satoshi</creatorcontrib><creatorcontrib>TOMITA, Naoto</creatorcontrib><creatorcontrib>FUJIMAKI, Katsumichi</creatorcontrib><creatorcontrib>FUJISAWA, Shin</creatorcontrib><creatorcontrib>WATANABE, Shinichiro</creatorcontrib><creatorcontrib>MATSUZAKI, Michio</creatorcontrib><title>Clinical significance of fragmented red cells after allogeneic bone marrow transplantation</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><description>To clarify the clinical significance of the presence of fragmented red cells (FRC) after allogeneic bone marrow transplantation (BMT), we measured the incidence and degree of FRC and their relationships to clinical features. The percentages of FRC (%FRC) were measured in 50 patients on weeks -2, 0, 2, 4, 6, 8, 10, and 12. The %FRC in pre-BMT patients (mean, 0.52%; range, 0.04%-1.56%) was higher than in healthy control subjects (mean, 0.08%; range, 0.02%-0.27%). The highest %FRC (&gt; or = 1.3%) were seen in 2 pre-BMT and 17 post-BMT patients. Eight patients who developed thrombotic microangiopathy (TMA) showed %FRC values that were significantly higher than those in patients without TMA. However, the timing of elevated %FRC was delayed until several days after the onset of intravascular hemolysis and/or a drop in platelet count. Of the patients who did not experience TMA, 5 patients with infection and 4 patients with acute graft-versus-host disease (GVHD) also showed significant elevation of %FRC during the clinical course. Furthermore, multivariate analysis results demonstrated that TMA and infection had a statistically significant effect on the high value of %FRC. These findings indicate that the appearance of FRC is a common phenomenon in patients undergoing BMT and is not a predictive factor for the early diagnosis of TMA, although FRC is one of the main laboratory findings in TMA. Furthermore, an increased %FRC is seen in other post-BMT clinical settings, such as infection and acute GVHD.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Bone Marrow Transplantation - adverse effects</subject><subject>Bone marrow, stem cells transplantation. Graft versus host reaction</subject><subject>Case-Control Studies</subject><subject>Erythrocytes - pathology</subject><subject>Female</subject><subject>Hemolysis</subject><subject>Hemolytic-Uremic Syndrome - blood</subject><subject>Hemolytic-Uremic Syndrome - diagnosis</subject><subject>Hemolytic-Uremic Syndrome - etiology</subject><subject>Humans</subject><subject>Incidence</subject><subject>Infection - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Predictive Value of Tests</subject><subject>Purpura, Thrombotic Thrombocytopenic - blood</subject><subject>Purpura, Thrombotic Thrombocytopenic - diagnosis</subject><subject>Purpura, Thrombotic Thrombocytopenic - etiology</subject><subject>Risk Factors</subject><subject>Time Factors</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><subject>Transplantation, Homologous</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpd0E1rGzEQBmBRGhLn49IfUEQhORQ2HUkraXVsTZIGAr2kl1wWrXZkZNaSK60p-fdRsMGQw6ARPAwzLyFfGNwyAP3j1z1w0wnOuk9kwTolG6F1-5kswHDZSM3gjJyXsgZgGlp9Ss4YV1x3Ui7Iy3IKMTg70RJWMfjaRoc0eeqzXW0wzjjSXMvhNBVq_YyZ2mlKK4wYHB1SRLqxOaf_dM42lu1k42znkOIlOfF2Knh1eC_I3_u75-Xv5unPw-Py51PjhBFzo4x2IJgblfOuBTC2ReM7ZIqBQmv4IIeRMaxfYT1zEpQdulG11QKMRlyQm_3cbU7_dljmfhPK-7o2YtqVXgswAG1X4bcPcJ12Odbdes606DgXuqLve-RyKiWj77c51ANfewb9e9z9Me6Kvx4m7oYNjkd6yLeC6wOwpYZcM40ulKNrJQempHgDtQ6Ggg</recordid><startdate>20030201</startdate><enddate>20030201</enddate><creator>KANAMORI, Heiwa</creator><creator>TAKAISHI, Yumiko</creator><creator>ISHIGATSUBO, Yoshiaki</creator><creator>TAKABAYASHI, Maki</creator><creator>TANAKA, Masatsugu</creator><creator>YAMAJI, Satoshi</creator><creator>TOMITA, Naoto</creator><creator>FUJIMAKI, Katsumichi</creator><creator>FUJISAWA, Shin</creator><creator>WATANABE, Shinichiro</creator><creator>MATSUZAKI, Michio</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20030201</creationdate><title>Clinical significance of fragmented red cells after allogeneic bone marrow transplantation</title><author>KANAMORI, Heiwa ; TAKAISHI, Yumiko ; ISHIGATSUBO, Yoshiaki ; TAKABAYASHI, Maki ; TANAKA, Masatsugu ; YAMAJI, Satoshi ; TOMITA, Naoto ; FUJIMAKI, Katsumichi ; FUJISAWA, Shin ; WATANABE, Shinichiro ; MATSUZAKI, Michio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-697c031cd6cfc4009a4e9f8e16106ea92b5bd11e6103af1c506ab8d6440000d93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Bone Marrow Transplantation - adverse effects</topic><topic>Bone marrow, stem cells transplantation. Graft versus host reaction</topic><topic>Case-Control Studies</topic><topic>Erythrocytes - pathology</topic><topic>Female</topic><topic>Hemolysis</topic><topic>Hemolytic-Uremic Syndrome - blood</topic><topic>Hemolytic-Uremic Syndrome - diagnosis</topic><topic>Hemolytic-Uremic Syndrome - etiology</topic><topic>Humans</topic><topic>Incidence</topic><topic>Infection - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Predictive Value of Tests</topic><topic>Purpura, Thrombotic Thrombocytopenic - blood</topic><topic>Purpura, Thrombotic Thrombocytopenic - diagnosis</topic><topic>Purpura, Thrombotic Thrombocytopenic - etiology</topic><topic>Risk Factors</topic><topic>Time Factors</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><topic>Transplantation, Homologous</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KANAMORI, Heiwa</creatorcontrib><creatorcontrib>TAKAISHI, Yumiko</creatorcontrib><creatorcontrib>ISHIGATSUBO, Yoshiaki</creatorcontrib><creatorcontrib>TAKABAYASHI, Maki</creatorcontrib><creatorcontrib>TANAKA, Masatsugu</creatorcontrib><creatorcontrib>YAMAJI, Satoshi</creatorcontrib><creatorcontrib>TOMITA, Naoto</creatorcontrib><creatorcontrib>FUJIMAKI, Katsumichi</creatorcontrib><creatorcontrib>FUJISAWA, Shin</creatorcontrib><creatorcontrib>WATANABE, Shinichiro</creatorcontrib><creatorcontrib>MATSUZAKI, Michio</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KANAMORI, Heiwa</au><au>TAKAISHI, Yumiko</au><au>ISHIGATSUBO, Yoshiaki</au><au>TAKABAYASHI, Maki</au><au>TANAKA, Masatsugu</au><au>YAMAJI, Satoshi</au><au>TOMITA, Naoto</au><au>FUJIMAKI, Katsumichi</au><au>FUJISAWA, Shin</au><au>WATANABE, Shinichiro</au><au>MATSUZAKI, Michio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical significance of fragmented red cells after allogeneic bone marrow transplantation</atitle><jtitle>International journal of hematology</jtitle><addtitle>Int J Hematol</addtitle><date>2003-02-01</date><risdate>2003</risdate><volume>77</volume><issue>2</issue><spage>180</spage><epage>184</epage><pages>180-184</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><abstract>To clarify the clinical significance of the presence of fragmented red cells (FRC) after allogeneic bone marrow transplantation (BMT), we measured the incidence and degree of FRC and their relationships to clinical features. The percentages of FRC (%FRC) were measured in 50 patients on weeks -2, 0, 2, 4, 6, 8, 10, and 12. The %FRC in pre-BMT patients (mean, 0.52%; range, 0.04%-1.56%) was higher than in healthy control subjects (mean, 0.08%; range, 0.02%-0.27%). The highest %FRC (&gt; or = 1.3%) were seen in 2 pre-BMT and 17 post-BMT patients. Eight patients who developed thrombotic microangiopathy (TMA) showed %FRC values that were significantly higher than those in patients without TMA. However, the timing of elevated %FRC was delayed until several days after the onset of intravascular hemolysis and/or a drop in platelet count. Of the patients who did not experience TMA, 5 patients with infection and 4 patients with acute graft-versus-host disease (GVHD) also showed significant elevation of %FRC during the clinical course. Furthermore, multivariate analysis results demonstrated that TMA and infection had a statistically significant effect on the high value of %FRC. These findings indicate that the appearance of FRC is a common phenomenon in patients undergoing BMT and is not a predictive factor for the early diagnosis of TMA, although FRC is one of the main laboratory findings in TMA. Furthermore, an increased %FRC is seen in other post-BMT clinical settings, such as infection and acute GVHD.</abstract><cop>Tokyo</cop><pub>Springer</pub><pmid>12627855</pmid><doi>10.1007/BF02983218</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0925-5710
ispartof International journal of hematology, 2003-02, Vol.77 (2), p.180-184
issn 0925-5710
1865-3774
language eng
recordid cdi_proquest_miscellaneous_73090048
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Adolescent
Adult
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Biological and medical sciences
Bone Marrow Transplantation - adverse effects
Bone marrow, stem cells transplantation. Graft versus host reaction
Case-Control Studies
Erythrocytes - pathology
Female
Hemolysis
Hemolytic-Uremic Syndrome - blood
Hemolytic-Uremic Syndrome - diagnosis
Hemolytic-Uremic Syndrome - etiology
Humans
Incidence
Infection - blood
Male
Medical sciences
Middle Aged
Predictive Value of Tests
Purpura, Thrombotic Thrombocytopenic - blood
Purpura, Thrombotic Thrombocytopenic - diagnosis
Purpura, Thrombotic Thrombocytopenic - etiology
Risk Factors
Time Factors
Transfusions. Complications. Transfusion reactions. Cell and gene therapy
Transplantation, Homologous
title Clinical significance of fragmented red cells after allogeneic bone marrow transplantation
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T12%3A46%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20significance%20of%20fragmented%20red%20cells%20after%20allogeneic%20bone%20marrow%20transplantation&rft.jtitle=International%20journal%20of%20hematology&rft.au=KANAMORI,%20Heiwa&rft.date=2003-02-01&rft.volume=77&rft.issue=2&rft.spage=180&rft.epage=184&rft.pages=180-184&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/BF02983218&rft_dat=%3Cproquest_cross%3E1879945031%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217382237&rft_id=info:pmid/12627855&rfr_iscdi=true